209 related articles for article (PubMed ID: 28189725)
1. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
2. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity.
Chapman JV; Gouazé-Andersson V; Cabot MC
Int J Oncol; 2010 Dec; 37(6):1591-7. PubMed ID: 21042729
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
Morad SA; Madigan JP; Levin JC; Abdelmageed N; Karimi R; Rosenberg DW; Kester M; Shanmugavelandy SS; Cabot MC
Biochem Pharmacol; 2013 Apr; 85(8):1057-65. PubMed ID: 23353700
[TBL] [Abstract][Full Text] [Related]
4. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
Chapman JV; Gouazé-Andersson V; Messner MC; Flowers M; Karimi R; Kester M; Barth BM; Liu X; Liu YY; Giuliano AE; Cabot MC
Biochem Pharmacol; 2010 Aug; 80(3):308-15. PubMed ID: 20385104
[TBL] [Abstract][Full Text] [Related]
6. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
Chapman JV; Gouazé-Andersson V; Karimi R; Messner MC; Cabot MC
Exp Cell Res; 2011 Jul; 317(12):1736-45. PubMed ID: 21396934
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
[TBL] [Abstract][Full Text] [Related]
10. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.
Morad SA; Levin JC; Shanmugavelandy SS; Kester M; Fabrias G; Bedia C; Cabot MC
Mol Cancer Ther; 2012 Nov; 11(11):2352-61. PubMed ID: 22962326
[TBL] [Abstract][Full Text] [Related]
11. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
Morad SAF; MacDougall MR; Abdelmageed N; Kao LP; Feith DJ; Tan SF; Kester M; Loughran TP; Wang HG; Cabot MC
Exp Cell Res; 2019 Aug; 381(2):256-264. PubMed ID: 31112736
[TBL] [Abstract][Full Text] [Related]
12. Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells.
Morad SA; Bridges LC; Almeida Larrea AD; Mayen AL; MacDougall MR; Davis TS; Kester M; Cabot MC
Cancer Lett; 2016 Jul; 376(2):199-204. PubMed ID: 27045476
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.
Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
15. Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation.
Shakor AB; Atia M; Ismail IA; Alshehri A; El-Refaey H; Kwiatkowska K; Sobota A
Biochim Biophys Acta; 2014 Dec; 1841(12):1672-82. PubMed ID: 25240837
[TBL] [Abstract][Full Text] [Related]
16. Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micelles.
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2017 Jul; 488(4):573-577. PubMed ID: 28533092
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
Turzanski J; Grundy M; Shang S; Russell N; Pallis M
Exp Hematol; 2005 Jan; 33(1):62-72. PubMed ID: 15661399
[TBL] [Abstract][Full Text] [Related]
18. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
Thomas H; Coley HM
Cancer Control; 2003; 10(2):159-65. PubMed ID: 12712010
[TBL] [Abstract][Full Text] [Related]
19. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
20. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics.
Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
Int J Oncol; 1999 Sep; 15(3):541-6. PubMed ID: 10427137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
